Patent 7608693 was granted and assigned to Regeneron Pharmaceuticals, Inc. on October, 2009 by the United States Patent and Trademark Office.
An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (KD), capable of blocking hIL-4 and hIL-13 activity.